Rau et al. published in Molecular Cancer Therapeutics

9. März 2022

Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer

Alexander Rau; Nicole Janssen; Lennart Kühl; Thomas Sell; Svetlana Kalmykova; Thomas E. Mürdter; Marc-H Dahlke; Christine Sers; Markus Morkel; Matthias Schwab; Roland E. Kontermann; Monilola A. Olayioye   


Current treatment options for patients with advanced colorectal cancers (CRC) include anti-EGFR/HER1 therapy with the blocking antibody cetuximab. Although a subset of patients with KRAS wild-type disease initially respond to the treatment, resistance develops in almost all cases. Relapse has been associated with the production of the ligand heregulin (HRG) and/or compensatory signaling involving the receptor tyrosine kinases HER2 and HER3. Here we provide evidence that triple HER receptor blockade based on a newly developed bispecific EGFRxHER3-targeting antibody (scDb-Fc) together with the HER2 blocking antibody trastuzumab effectively inhibited HRG-induced HER receptor phosphorylation, downstream signaling, proliferation and stem cell expansion of DiFi and LIM1215 CRC cells. Comparative analyses revealed that the biological activity of scDb-Fc plus trastuzumab was sometimes even superior to that of the combination of the parental antibodies, with PI3K/Akt pathway inhibition correlating with improved therapeutic response and apoptosis induction as seen by single cell analysis. Importantly, growth suppression by triple HER targeting was recapitulated in primary KRAS wild-type patient-derived organoid (PDO) cultures exposed to HRG. Collectively, our results provide strong support for a pan-HER receptor blocking approach to combat anti-EGFR therapy resistance of KRAS wild-type CRC tumors mediated by the upregulation of HRG and/or HER2/HER3 signaling.


doi: 10.1158/1535-7163.MCT-21-0818

Zum Seitenanfang